TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Repros Therapeutics finds funding Repros Therapeutics Inc. on Tuesday said it has secured about $1 million in financing through a share sale to an unnamed investor. (RPRX) feeds.bizjournals.com |
Senate Panel to Vote Tuesday on Bill The Senate Finance Committee will vote next Tuesday on a $829 billion health-care bill, after months of efforts to gain consensus on the massive overhaul. online.wsj.com |
NeoGenomics Reports Third Quarter 2009 Results (PR Newswire) NeoGenomics, Inc. , a leading provider of cancer-focused genetic testing services today reported its results for the third quarter of 2009. us.rd.yahoo.com |
Graft-Versus-Host Disease: Failures and Future Opportunities Michael Becker submits:In September 2009, Osiris Therapeutics, Inc. (OSIR) reported preliminary results from two Phase III trials evaluating its Prochymal product candidate for the treatment of acute graft-versus-host disease [GVHD]. Unfortunately, neither trial reached its primary endpoint, sending shares from $14 to a 52-week low of $5.35 by November 2009. The results were the latest in a number of late-stage, clinical trial setbacks for the treatment of GVHD [see table 1], prompting us to review this very complicated disease in search of future treatment opportunities. What Is GVHD? Complete Story » seekingalpha.com |
Health Firms Scramble to Assess Shift A number of health-care firms reiterated support for a sector overhaul thrown into doubt by Republican Scott Brown's win. online.wsj.com |